Avelumab in metastatic castration-resistant prostate cancer (mCRPC).

F Fakhrejahani, RA Madan, WL Dahut, F Karzai… - 2017 - ascopubs.org
159 Background: Despite recent progress, mCRPC remains a lethal disease. While
programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors have shown activity in …
被引用次数：37 相关文章

Avelumab in metastatic castration-resistant prostate cancer (mCRPC).

F Fakhrejahani, RA Madan, WL Dahut, M Bilusic… - 2017 - ascopubs.org
5037 Background: Despite recent progress, mCRPC remains a lethal disease. While
programmed cell death 1 (PD-1) and PD-1 ligand (PD-L1) inhibitors have shown activity in …